J P Morgan Chase & Co restated their neutral rating on shares of GlaxoSmithKline PLC (NYSE:GSK) in a report published on Wednesday.

Several other equities research analysts have also commented on GSK. Citigroup Inc. lowered GlaxoSmithKline PLC from a buy rating to a neutral rating in a research note on Wednesday, July 5th. Zacks Investment Research raised GlaxoSmithKline PLC from a hold rating to a buy rating and set a $47.00 price target on the stock in a research note on Tuesday, July 18th. BidaskClub lowered GlaxoSmithKline PLC from a sell rating to a strong sell rating in a research note on Monday, July 24th. TheStreet lowered GlaxoSmithKline PLC from a b rating to a c+ rating in a research note on Wednesday, July 26th. Finally, Argus reissued a buy rating and set a $50.00 price target on shares of GlaxoSmithKline PLC in a research note on Thursday, August 31st. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating and seven have issued a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus target price of $44.33.

GlaxoSmithKline PLC (GSK) traded down 0.63% during trading on Wednesday, reaching $40.84. The company had a trading volume of 8,971,913 shares. The stock has a market capitalization of $99.81 billion, a price-to-earnings ratio of 39.57 and a beta of 1.03. The firm has a 50-day moving average of $40.51 and a 200-day moving average of $41.53. GlaxoSmithKline PLC has a 1-year low of $37.20 and a 1-year high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last announced its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.68 by $0.02. The business had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a return on equity of 114.93% and a net margin of 6.48%. On average, analysts anticipate that GlaxoSmithKline PLC will post $2.87 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “J P Morgan Chase & Co Reaffirms Neutral Rating for GlaxoSmithKline PLC (GSK)” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://theolympiareport.com/2017/10/21/j-p-morgan-chase-co-reaffirms-neutral-rating-for-glaxosmithkline-plc-gsk.html.

The firm also recently declared a quarterly dividend, which was paid on Thursday, October 12th. Shareholders of record on Friday, August 11th were issued a $0.491 dividend. The ex-dividend date was Wednesday, August 9th. This is an increase from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a yield of 4.81%. GlaxoSmithKline PLC’s payout ratio is 198.00%.

A number of institutional investors and hedge funds have recently modified their holdings of GSK. Russell Investments Group Ltd. acquired a new position in GlaxoSmithKline PLC in the 1st quarter valued at $578,000. SG Americas Securities LLC acquired a new position in GlaxoSmithKline PLC in the 1st quarter valued at $399,000. Stratos Wealth Partners LTD. raised its holdings in GlaxoSmithKline PLC by 76.4% in the 1st quarter. Stratos Wealth Partners LTD. now owns 20,971 shares of the pharmaceutical company’s stock valued at $884,000 after acquiring an additional 9,084 shares during the last quarter. FMR LLC raised its holdings in GlaxoSmithKline PLC by 11.7% in the 1st quarter. FMR LLC now owns 23,635,038 shares of the pharmaceutical company’s stock valued at $996,452,000 after acquiring an additional 2,482,009 shares during the last quarter. Finally, Lakeview Capital Partners LLC raised its holdings in GlaxoSmithKline PLC by 5.2% in the 1st quarter. Lakeview Capital Partners LLC now owns 8,737 shares of the pharmaceutical company’s stock valued at $368,000 after acquiring an additional 428 shares during the last quarter. Institutional investors own 9.28% of the company’s stock.

About GlaxoSmithKline PLC

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.